VYZULTA

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Hong Kong SAR China, Turkey.

Active ingredients

The drug VYZULTA contains one active pharmaceutical ingredient (API):

1	Latanoprostene bunod UNII I6393O0922 - LATANOPROSTENE BUNOD
	Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
	Read more about Latanoprostene bunod

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYZULTA Οphthalmic solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE06		S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	503121080003002, 503121080003102
CA	Health Products and Food Branch	02484218
HK	Department of Health Drug Office	66408
TR	İlaç ve Tıbbi Cihaz Kurumu	8681738610048
US	FDA, National Drug Code	24208-504